In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases

This publication has 16 references indexed in Scilit:

• Worldwide Prevalence of Antimicrobial Resistance inStreptococcus pneumoniae, Haemophilus influenzae,andMoraxella catarrhalisin the SENTRY Antimicrobial Surveillance Program, 1997–1999
  Clinical Infectious Diseases, 2001
• In Vitro Activities of the Glycylcycline GAR-936 against Gram-Positive Bacteria
  Antimicrobial Agents and Chemotherapy, 2000
• Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates
  Diagnostic Microbiology and Infectious Disease, 2000
• In Vitro and In Vivo Antibacterial Activities of a Novel Glycylcycline, the 9- t -Butylglycylamido Derivative of Minocycline (GAR-936)
  Antimicrobial Agents and Chemotherapy, 1999
• Two investigational glycylcyclines, DMG-DMDOT and DMG-MINO antimicrobial activity studied against gram-positive species
  Diagnostic Microbiology and Infectious Disease, 1996
• In-vitro activity of two glycylcyclines against enterococci resistant to other agents
  Journal of Antimicrobial Chemotherapy, 1995
• Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to new glycylcyclines in comparison with those to older tetracyclines
  Antimicrobial Agents and Chemotherapy, 1994
• N,N-dimethylglycyl-amido derivative of minocycline and 6-demethyl-6-desoxytetracycline, two new glycylcyclines highly effective against tetracycline-resistant gram-positive cocci
  Antimicrobial Agents and Chemotherapy, 1994
• In vitro activities of two glycylcyclines against gram-positive bacteria
  Antimicrobial Agents and Chemotherapy, 1994
• In vitro activity of DMG-mino and DMG-DM Dot, two new glycylcyclines, against anaerobic bacteria
  European Journal of Clinical Microbiology & Infectious Diseases, 1993